Market Research Reports, Inc.

Gastric Cancer – Pipeline Review, H1 2018 Market Report; Launched via

Gastric Cancer – Pipeline Review, H1 2018, provides an overview of the Gastric Cancer (Oncology) pipeline landscape.

Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. Risk factors include smoking, pernicious anemia, stomach polyps, infection with helicobacter pylori and family history of stomach cancer. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Gastric Cancer – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Gastric Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastric Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 14, 80, 99, 11, 97, 17 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 9, 3, 1, 9 and 2 molecules, respectively.

Gastric Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Gastric Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gastric Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gastric Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gastric Cancer (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gastric Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gastric Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Spanning over 1283 pages Gastric Cancer – Pipeline Review, H1 2018” report covers Introduction, Gastric Cancer – Overview, Gastric Cancer – Therapeutics Development, Gastric Cancer – Therapeutics Assessment, Gastric Cancer – Companies Involved in Therapeutics Development, Gastric Cancer – Drug Profiles, Gastric Cancer – Dormant Projects, Appendix. This report Covered Companies few are – Aurigene Discovery Technologies Ltd, Avipep Pty Ltd, Basilea Pharmaceutica Ltd, Bayer AG, BeiGene Ltd, CSPC Pharmaceutical Group Limited, Curaxys SL, Cytori Therapeutics Inc, Daiichi Sankyo Co Ltd, Exelixis Inc, F-star Biotechnology Ltd, F. Hoffmann-La Roche Ltd.

Please visit this link for more details:

Find all Pharma and Healthcare Reports at:

Related Reports;

Head And Neck Cancer – Pipeline Review, H1 2018 – Visit at –

Chronic Urticaria Or Hives – Pipeline Review, H1 2018 –

About Market Research Reports, Inc.

Market Research Reports® Inc. is world’s largest store offering quality market research, SWOT analysis, competitive intelligence and industry reports. We help Fortune 500 to Start-Ups with the latest market research reports on global & regional markets which comprise key industries, leading market players, new products and latest industry analysis & trends.